<DOC>
	<DOCNO>NCT00095732</DOCNO>
	<brief_summary>The purpose study determine effective dose new enzyme therapy oral nutrient absorption cystic fibrosis ( CF ) subject exocrine pancreatic insufficiency .</brief_summary>
	<brief_title>Oral TheraCLEC™ - Total Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<criteria>Pancreatic insufficiency ( PI ) document fecal elastase &lt; 100 mcg/gram measure screening Diagnosis CF base upon follow criterion : two clinical feature consistent CF AND either genotype two identifiable mutation consistent CF OR sweat chloride &gt; 60 mEq/L quantitative pilocarpine iontophoresis Forced Expiratory Volume Over One Second ( FEV1 ) ≥30 % predict Clinically stable evidence acute upper low respiratory tract infection Pregnancy , breastfeed childbearing potential and/or willing use accept method birth control enrollment study History fibrosing colonopathy History liver transplant lung transplant Unable discontinue enteral tube feeding study Subject weight &lt; 40 kg Known hypersensitivity food additive Participation investigational study drug , biologic , device currently approve marketing within 30 day prior screen Unable discontinue use pancreatic enzyme 72hour period condition investigator believe would interfere intent study would make study participation best interest subject</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Pancreatic Insufficiency</keyword>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Enzymes</keyword>
</DOC>